Evaluation of side effects of sildenafil in group of young healthy volunteers

被引：12

作者：

Dündar M. ^{[1
]}

Koçak I. ^{[1
]}

Dündar S.O. ^{[2
]}

Erol H. ^{[1
]}

机构：

[1] Department of Urology, Adnan Menderes University, Medical School

[2] Department of Ophthalmology, Adnan Menderes University, Medical School

来源：

International Urology and Nephrology | 2001年 / 32卷 / 4期

关键词：

Normal potency; Side effect; Sildenafil; Young volunteer;

D O I：

10.1023/A:1015056416501

中图分类号：

学科分类号：

摘要：

We evaluated the safety and side effects of sildenafil in a group of sexually active volunteers younger than 40 years under conditions without sexual stimulation. Single oral dose of 50 mg dildenafil (n = 20) or placebo (n = 20) was randomly administered to 40 sexually active volunteers with the mean age of 26.80 ± 5.29 in sildenafil group and 25.70 ± 4.95 in placebo group. All the subjects were informed about the study, but not about the medicine. The following tests were performed immediately before and 90 minutes after the administration of the medicine: resting heart rate, blood pressure, electrocardiogram, visual acuity, color vision. The subjects were also asked to describe any discomfort or difference. Mann Whitney U test was used for statistical analyses. The only statistically significant difference was between heart rates before and after the administration of the sildenafil (p = 0.02). Color vision, visual acuity tests yielded no differences. The decrease in blood pressure was not significant. The most common side effects were flushing (75% and 0%), headache (50% and 5%), dyspepsia (15% and 5%), unintentional incomplete sexual arousal (15% and 0%) and palpitation (15% and 10%) in groups of sildenafil and placebo, respectively. The only serious side effect requiring medical treatment was arthralgia on the knee in one subject. Although these side effects can be acceptable, the likelihood of these side effects needs to be made clear to potential users of this medication.

引用

页码：705 / 708

页数：3

共 19 条

[1]

Boolel M., Gepi-Attee S., Gingell J.C., Allen M.J., Sidenafil. A novel effective oral therapy for male erectile dysfunction, Br J Urol, 78, pp. 257-261, (1996)

[2]

Ballard S.A., Et al., Sildenafil, an inhibitor of the phosphodiesterase type 5, enhances nitric oxide mediated relaxation of human corpus cavernosum, Int J Impot Res, 8, (1996)

[3]

Tarrett N.K., Bell A.S., Brown D., Ellis P., Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction, Bioorganic and Medicinal Chemistry Letters, 6, pp. 1819-1824, (1996)

[4]

Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A., Oral Sildenafil in the treatment of erectile dysfunction, N Engl J Med, 338, pp. 1397-1404, (1998)

[5]

Wagner G., Saenz De Tejada I., Update on male erectile dysfunction, BMJ, 316, pp. 678-682, (1998)

[6]

Morales A., Gingell C., Collins M., Wicker P.A., Osterloh I.H., Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction, Int J Impot Res, 10, pp. 69-74, (1998)

[7]

Viagra deaths often occur within 4-5 hour - FDA safety update, FDC Pink, 60, (1998)

[8]

Padma-Nathan H., Steers W.D., Wicker P.A., Efficacy and safety oral sildenafil in the treatment of erectile dysfunction: A double blind, placebo controlled study of 329 patients, Int J Clin Practice, 52, 6, pp. 375-379, (1998)

[9]

31 deaths associated with Viagra in UK, Scrip, 2471, (1999)

[10]

Walker D.K., Ackland M.J., James G.C., Muirhead G.J., Rance D.J., Wastall P., Wright P.A., Pharmacokinetics and metabolism of sildenafil in mouse, rate, rabbit, dog and man, Xenobiotica, 29, 3, pp. 297-310, (1999)

← 1 2 →